BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 24656771)

  • 1. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
    Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
    Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.
    Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM
    J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential Self-interaction of DNA Methyltransferase DNMT3A Subunits Containing the R882H Cancer Mutation Leads to Dominant Changes of Flanking Sequence Preferences.
    Mack A; Emperle M; Schnee P; Adam S; Pleiss J; Bashtrykov P; Jeltsch A
    J Mol Biol; 2022 Apr; 434(7):167482. PubMed ID: 35131259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
    Anteneh H; Fang J; Song J
    Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns.
    Emperle M; Adam S; Kunert S; Dukatz M; Baude A; Plass C; Rathert P; Bashtrykov P; Jeltsch A
    Nucleic Acids Res; 2019 Dec; 47(21):11355-11367. PubMed ID: 31620784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNMT3A R882H mutant displays altered flanking sequence preferences.
    Emperle M; Rajavelu A; Kunert S; Arimondo PB; Reinhardt R; Jurkowska RZ; Jeltsch A
    Nucleic Acids Res; 2018 Apr; 46(6):3130-3139. PubMed ID: 29518238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
    Khrabrova DA; Yakubovskaya MG; Gromova ES
    Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia.
    Khrabrova DA; Loiko AG; Tolkacheva AA; Cherepanova NA; Zvereva MI; Kirsanova OV; Gromova ES
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A/R882H complexes.
    Emperle M; Dukatz M; Kunert S; Holzer K; Rajavelu A; Jurkowska RZ; Jeltsch A
    Sci Rep; 2018 Sep; 8(1):13242. PubMed ID: 30185810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
    Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
    Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
    Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
    Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
    Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
    Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.
    Park SH; Choi JC; Kim SY; Yi J; Oh SH; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
    Biomed Res Int; 2015; 2015():723682. PubMed ID: 25650308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.
    Kim SJ; Zhao H; Hardikar S; Singh AK; Goodell MA; Chen T
    Blood; 2013 Dec; 122(25):4086-9. PubMed ID: 24167195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of
    Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A
    Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.
    Scheller M; Ludwig AK; Göllner S; Rohde C; Krämer S; Stäble S; Janssen M; Müller JA; He L; Bäumer N; Arnold C; Gerß J; Schönung M; Thiede C; Niederwieser C; Niederwieser D; Serve H; Berdel WE; Thiem U; Hemmerling I; Leuschner F; Plass C; Schlesner M; Zaugg J; Milsom MD; Trumpp A; Pabst C; Lipka DB; Müller-Tidow C
    Nat Cancer; 2021 May; 2(5):527-544. PubMed ID: 35122024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.